What is the recommended management and treatment for community-acquired pneumonia?

Management and Treatment of Community-Acquired Pneumonia

For outpatients without comorbidities, treat with a macrolide (azithromycin, clarithromycin, or erythromycin) or doxycycline as first-line therapy; for those with comorbidities (COPD, diabetes, renal/heart failure, malignancy) or recent antibiotic use, use a respiratory fluoroquinolone (moxifloxacin, levofloxacin 750mg, or gemifloxacin) or combine a β-lactam with a macrolide. 1

Site of Care Decision

The decision to hospitalize should follow a systematic 3-step process 2:

1. Assess safety of home care - Evaluate for conditions compromising outpatient management
2. Calculate the Pneumonia Severity Index (PSI) - Risk classes I, II, and III can be managed outpatient
3. Apply clinical judgment - Override scoring when clinically indicated

Outpatient Treatment Algorithm

Previously Healthy Patients (No Comorbidities)

Without recent antibiotic use:

• Macrolide monotherapy (azithromycin, clarithromycin, or erythromycin) 1
• Alternative: Doxycycline 1

With recent antibiotic use (within 3 months):

• Respiratory fluoroquinolone alone (moxifloxacin, gemifloxacin, or levofloxacin 750mg) 1
• Alternative: Advanced macrolide plus high-dose amoxicillin (1g three times daily) or amoxicillin-clavulanate 2

Patients with Comorbidities

Comorbidities include: COPD, diabetes, renal failure, heart failure, liver disease, malignancy, alcoholism, asplenia, or immunosuppression 1

First-line options:

• Respiratory fluoroquinolone monotherapy 1
• β-lactam (high-dose amoxicillin, amoxicillin-clavulanate, ceftriaxone, cefpodoxime, or cefuroxime 500mg twice daily) plus macrolide 1

Critical caveat: In regions with high-level macrolide resistance (≥25% with MIC ≥16 mg/mL), avoid macrolide monotherapy even in healthy patients 1

Inpatient Non-ICU Treatment

Preferred regimens (equal efficacy):

• Respiratory fluoroquinolone monotherapy 1
• β-lactam (cefotaxime, ceftriaxone, or ampicillin) plus macrolide 1

For penicillin-allergic patients: Use respiratory fluoroquinolone 1

Route of administration: Most hospitalized patients with non-severe CAP can receive oral antibiotics if no contraindications exist 3. The combination of oral amoxicillin plus macrolide is preferred for those requiring admission 3

ICU/Severe CAP Treatment

Standard severe CAP (no Pseudomonas risk):

• β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus either azithromycin OR a respiratory fluoroquinolone 1

This combination approach is strongly recommended based on evidence showing improved mortality outcomes with dual therapy in severe disease 1.

For Pseudomonas risk factors (structural lung disease, recent hospitalization, recent broad-spectrum antibiotics):

• Antipseudomonal β-lactam (piperacillin-tazobactam, cefepime, imipenem, or meropenem) PLUS
• Either: Ciprofloxacin or levofloxacin 750mg 1
• OR: Aminoglycoside plus azithromycin or antipneumococcal fluoroquinolone 1

For suspected MRSA (recent influenza, necrotizing pneumonia, cavitation):

• Add vancomycin or linezolid to the above regimens 1

For β-lactam allergic patients with severe CAP:

• Respiratory fluoroquinolone plus aztreonam 1

Duration of Therapy

Minimum 5 days of treatment for all patients, with the following criteria met before stopping 1:

• Afebrile for 48-72 hours
• No more than 1 sign of clinical instability (temperature >37.8°C, heart rate >100, respiratory rate >24, systolic BP <90mmHg, oxygen saturation <90%, inability to maintain oral intake, abnormal mental status)

Shorter duration (3-5 days) may be appropriate for outpatients and non-severe hospitalized CAP who achieve clinical stability 4, 5

Extended duration (14-21 days) required for Legionella, Staphylococcus aureus, or gram-negative enteric bacilli 3

Transition to Oral Therapy

Switch from IV to oral when:

• Hemodynamically stable
• Clinically improving
• Able to ingest medications
• Functioning gastrointestinal tract 1

Discharge immediately after oral switch - inpatient observation while on oral therapy is unnecessary 1

Special Considerations

Aspiration Pneumonia

Use amoxicillin-clavulanate or clindamycin 2

Influenza with Bacterial Superinfection

Use β-lactam or respiratory fluoroquinolone, targeting S. pneumoniae and S. aureus 1

Corticosteroids

For severe CAP: Consider systemic corticosteroids within 36 hours of admission to reduce ARDS risk and treatment duration 6

For non-severe CAP: Avoid corticosteroids 5

Failure to Improve

If no clinical response within 3-5 days, systematically review 1:

• Incorrect diagnosis
• Resistant or unusual pathogen
• Inadequate antibiotic dose/route
• Complications (empyema, abscess)
• Drug fever or adverse reaction

For non-severe CAP failing amoxicillin monotherapy, add or substitute a macrolide 3. For severe CAP not responding to combination therapy, consider adding rifampicin 3

Follow-up

Clinical review at 6 weeks for all patients 3

Repeat chest radiograph at 6 weeks for:

• Persistent symptoms or physical signs
• Smokers over age 50
• Higher risk for underlying malignancy 3

No need to repeat CXR before discharge if satisfactory clinical recovery 3

Key Pitfalls to Avoid

1. Do not use macrolide monotherapy in hospitalized patients or those with comorbidities - resistance patterns make this inadequate 1
2. Do not delay antibiotics in ED patients - first dose should be given in the emergency department 1
3. Do not continue IV therapy once oral criteria are met - this unnecessarily prolongs hospitalization 1
4. Do not treat beyond clinical stability - extending antibiotics beyond 5 days when criteria are met increases resistance and adverse effects 1
5. Fluoroquinolones are not first-line for community use due to resistance concerns and side effect profiles, but are appropriate for hospitalized patients 3